Regeneron antibody treatment reduces risk of death in hospitalized Covid patients, study finds

An antibody combination made by Regeneron reduces the risk of death when given to patients with severe Covid-19 who have not mounted a natural antibody response of their own. Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joined "Squawk Box" on Wednesday to discuss.
Wed, Jun 16 20216:28 AM EDT